The US subsidiary of Ferring Pharmaceuticals presented the results of a six-month safety and efficacy study, demonstrating that Euflexxa (1% sodium hyaluronate) was effective at decreasing the pain of knee osteoarthritis compared to saline after 26 weeks, at the annual meeting of the American Academy of Orthopedic Surgeons, held in Las Vegas, Nevada.
The multicenter, 26-week, randomized, double-blind trial compared Euflexxa and intra-articular buffered saline for level of pain following a 50-Foot Walk Test, measured by 100 mm visual analog scale. The 586 patients with chronic idiopathic knee OA were randomized to treatment with either product in a 1:1 ratio. Each patient received one weekly injection for three weeks with nine follow-up visits over 26 weeks after the first injection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze